SEMAX [10mg]

Preclinical research has focused on SEMAX's ability to upregulate brain-derived neurotrophic factor (BDNF) and its receptor TrkB in hippocampal and frontal cortical tissue under conditions of AF64A-induced neurodegeneration and acute hypoxia. Dolotov, Karpenko, and colleagues at the Institute of Molecular Genetics documented SEMAX-induced changes in hippocampal BDNF and NGF transcription in rodent stress models. Separate lines of research examined the compound's effects on dopaminergic and serotonergic signaling, enkephalin-degrading enzyme inhibition, and cortical EEG activity. All findings referenced here derive from preclinical models and have not been validated in controlled human clinical trials.